NuVation Bio Inc.
Clinical trials sponsored by NuVation Bio Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing therapies for metabolic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a common heartburn pill change how a cancer drug works? Results expected Feb 2027 (estimated)
- New hope for Hard-to-Treat cancers: NUV-1511 enters human trials Results expected Mar 2027 (estimated)
-
New hope for brain tumor patients: targeted drug shows promise in phase 3 trial
Disease control Recruiting nowThis study tests a drug called safusidenib in people with a type of brain tumor (glioma) that has a specific gene mutation (IDH1). The trial has three parts: one for recurrent tumors, one for high-risk tumors after standard treatment, and one for a specific tumor type after surge…
Phase 3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill aims to stop lung cancer recurrence in High-Risk patients
Disease control Recruiting nowThis phase 3 trial tests whether the drug taletrectinib can prevent non-small cell lung cancer from coming back after surgery in people with a specific genetic change (ROS1 fusion). About 180 participants will receive either taletrectinib or a placebo daily for several years. The…
Phase 3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New lung cancer drug aims to outperform current standard in advanced ROS1-positive patients
Disease control Recruiting nowThis study tests a new drug, taletrectinib, against the current standard drug crizotinib in people with a specific type of advanced lung cancer (ROS1-positive NSCLC) who have not had targeted therapy before. About 194 participants will be randomly assigned to take either taletrec…
Phase 3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC